Strategic Sarepta partnership and FDA filing position Arrowhead for a transformative leap in RNAi therapeutics ...
Morgan Stanley analyst Michael Ulz maintained a Hold rating on Arrowhead Pharmaceuticals (ARWR – Research Report) today and set a price target ...
Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for ...
After the market close on Tuesday, Iris reported first-quarter Bitcoin BTC/USD mining revenue of $49.6 million. The company ...
Arrowhead Pharmaceuticals, Inc. ( (ARWR) ) has released its Q4 earnings. Here is a breakdown of the information Arrowhead Pharmaceuticals, Inc.
The deal allows the Swiss company to develop cell therapies in-house. (The Wall Street Journal) Sarepta Therapeutics and ...
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) shares are trading higher Tuesday after the company announced a global ...
Sarepta Therapeutics said it will pay Arrowhead Pharmaceuticals $500 million in cash for a series of experimental RNA-based ...
Q4 2024 Earnings Conference Call November 26, 2024 4:30 PM ET. Company Participants. Vince Anzalone - VP, IR Chris Anzalone - Preside ...
Stocktwits on MSN1d
Arrowhead Pharma Stock Soars Pre-Market On $825M Sarepta Licensing Deal: Retail Activity Hits Year-HighShares of Arrowhead Pharmaceuticals ($ARWR) surged as much as 22% in pre-market trading on Tuesday after announcing a $825 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback